Rheumatology

Back to articles

Tofacitinib outperforms MTX as initial RA treatment

KEY POINT

Initial treatment with tofacitinib (Xeljanz—Pfizer) monotherapy was superior to methotrexate (MTX) in patients with active moderate-to-severe rheumatoid arthritis (RA) who had not previously received MTX or therapeutic doses of MTX.

SOURCES

Lee EB et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.